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Effect of induced hypoglycemia on 
inflammation and oxidative stress 
in type 2 diabetes and control 
subjects
Hassan Kahal1,2,8, Anna Halama3,8, Ahmed Aburima2, Aditya M. Bhagwat3, 
Alexandra E. Butler4*, Johannes Graumann5,6, Karsten Suhre5, Thozhukat Sathyapalan1 & 
Stephen L. Atkin7
Intensive diabetes control has been associated with increased mortality in type 2 diabetes (T2DM); 
this has been suggested to be due to increased hypoglycemia. We measured hypoglycemia-induced 
changes in endothelial parameters, oxidative stress markers and inflammation at baseline and after 
a 24-hour period in type 2 diabetic (T2DM) subjects versus age-matched controls. Case-control study: 
10 T2DM and 8 control subjects. Blood glucose was reduced from 5 (90 mg/dl) to hypoglycemic levels 
of 2.8 mmol/L (50 mg/dl) for 1 hour by incremental hyperinsulinemic clamps using baseline and 24 hour 
samples. Measures of endothelial parameters, oxidative stress and inflammation at baseline and 
at 24-hours post hypoglycemia were performed: proteomic (Somalogic) analysis for inflammatory 
markers complemented by C-reactive protein (hsCRP) measurement, and proteomic markers and 
urinary isoprostanes for oxidative measures, together with endothelial function. Between baseline 
and 24 -hours after hypoglycemia, 15 of 140 inflammatory proteins differed in T2DM whilst only 1 of 
140 differed in controls; all returned to baseline at 24-hours. However, elevated hsCRP levels were 
seen at 24-hours in T2DM (2.4 mg/L (1.2–5.4) vs. 3.9 mg/L (1.8–6.1), Baseline vs 24-hours, P < 0.05). In 
patients with T2DM, between baseline and 24-hour after hypoglycemia, only one of 15 oxidative stress 
proteins differed and this was not seen in controls. An increase (P = 0.016) from baseline (73.4 ng/mL) to 
24 hours after hypoglycemia (91.7 ng/mL) was seen for urinary isoprostanes. Hypoglycemia resulted in 
inflammatory and oxidative stress markers being elevated in T2DM subjects but not controls 24-hours 
after the event.
While type 2 diabetes (T2DM) is associated with an increased risk of cardiovascular disease1, strict glycemic 
control does not result in obvious cardiovascular benefit in people with T2DM2–4. A link between strict glycemic 
control, hypoglycemia and increased cardiovascular morbidity and mortality has been observed in clinical stud-
ies5,6. Although the underlying mechanism remains unclear, increased inflammatory cytokines and a leukocytosis 
are reported after hypoglycemia7,8, suggesting a link between hypoglycemia and inflammation.
It is well recognized that oxidative stress leads to damage of proteins and deoxyribonucleic acid (DNA)9 
and contributes to the diabetic complications of retinopathy, nephropathy, neuropathy and cardiovascu-
lar disorders10–13, and is directly linked to vascular inflammation, precipitating both endothelial cell dysfunc-
tion and vascular damage14. Oxidative stress results from excessive generation of free radicals and/or deficient 
defense mechanisms15, and leads to a disturbance of the physiological redox state16. The membrane associated 
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nicotinamide dinucleotide phosphate oxidase enzyme complex is the primary source of reactive species in the 
vasculature, leading to superoxide generation17,18. Cytokines and hormones involved in the pathogenesis of vas-
cular disease up-regulate vascular superoxide production17. The inflammation generated, in turn, can precipitate 
oxidative stress, further perpetuating the negative effects19,20. The endothelium is important in maintaining vascu-
lar homeostasis21 and endothelial dysfunction involves an impaired ability to regulate vascular tone together with 
anti-inflammatory and anticoagulatory alterations of the vasculature22. Moderate hypoglycemia has been shown 
to increase activation of prothrombotic and proinflammatory effects in type 1 diabetes23; therefore, in this study, 
we examined inflammatory markers, oxidative stress and endothelial function following iatrogenic hypoglycemia 
in subjects with and without T2DM24.
Material and Methods
Study design. A case-control study of T2DM subjects and age-matched controls. The study was approved by 
the Yorkshire and the Humber Research Ethics Committee and all study participants signed an informed consent 
form prior to participation. All institutional policies were followed for conductance of this study.
Study participants. Healthy individuals and T2DM subjects were recruited from adverts placed in Hull 
Royal Infirmary, University of Hull, and in the local newspaper. Study inclusion criteria included both Caucasian 
men and women between 40 and 60 years of age who were non-smokers. Subjects in the normal control group 
had no chronic medical condition and were on no medications. Subjects in the T2DM group had had T2DM for 
less than 10 years with no history of microvascular disease (retinopathy, nephropathy or neuropathy), glycated 
hemoglobin (HbA1C) ≤9.5% (80.3 mmol/mol), and were treated with diet or oral medication only. All female 
patients were postmenopausal and were not taking any hormonal preparation. Exclusion criteria for both groups 
included, chronic medical conditions, use of anti-platelet medications, current smokers, evidence of ischemia 
on echocardiogram (ECG), a history of drop attacks, alcohol or drug abuse, psychiatric illness, or a history of 
seizures. No patients were on statin or antihypertensive therapy.
Subjects who fulfilled the study inclusion/exclusion criteria were screened, following a 10 hour fast, under-
going an ECG to rule out ischemia, a clinical examination, and routine blood tests to rule out anemia, hyperlipi-
demia, renal or hepatic impairment. Subjects in the control group had an oral glucose tolerance test to rule out 
diabetes. T2DM subjects had a diabetic foot examination to rule out diabetic neuropathy, a urine test for albumin/
creatinine ratio to rule out diabetic nephropathy, and retinal screening (if this had not been performed within the 
last 6 months) to rule out diabetic retinopathy. All participants had an Endo-Pat test, as described below, to assess 
baseline endothelial function.
Hyperinsulinemic euglycemic-hypoglycemic clamp studies. The clamp study was performed 
within 4 weeks of the screening visit when participants were asked to avoid exercise, caffeine and high 
antioxidant-containing food for 24 hours (assessed by food diary) prior to the procedure. Individuals with T2DM 
on oral medications were asked to stop their oral hypoglycemic agents two days prior to the visit. This visit was 
preceded by at least a 10 hour fast. Subjects provided an early morning urine sample.
The clamp procedure was performed as previously described24. The insulin infusion rate was constant 
throughout the clamp [60 mU/body surface area (m2)/min], while the rate of the 20% dextrose infusion was 
adjusted every 5 minutes to achieve the target blood glucose level. Body surface area (m2) was calculated as 
[0.007184 × (height(cm)^0.725) × (weight(kg)^0.425)]. Baseline glucose was 6.2 ± 1.1 mmol/l (112 ± 20 mg/dl) 
for T2DM that was reduced to 5.0 ± 0.5 mmol/l (90 ± 9 mg/dl) with the clamp for one hour, whilst the control 
group was maintained at 4.8 ± 0.5 mmol/l (86 ± 9 mg/dl) for one hour. The blood glucose level was dropped grad-
ually to hypoglycemia, over 1 hour, to 2.8 mmol/L (50 mg/dl) and maintained at 2.8 mmol/L for 1 hour (hypogly-
caemic clamp).
Twenty-four hours after the clamp study, in the morning immediately after and following a 10 hour fast, sub-
jects provided an early morning urine sample, blood was taken and the Endo-Pat was performed.
Biochemical markers. Urine samples were collected, and aliquots stored at −20 °C until batch analy-
sis. Blood samples were separated immediately by centrifugation at 2000g for 15 minutes at 4 °C, and the ali-
quots were stored at −80 °C, within 30 minutes of blood collection, until batch analysis. High sensitivity 
C-reactive protein (hsCRP) was measured using Synchron systems CRPH reagent kit (Beckman-Coulter, UK) 
as per manufacturer’s protocol. Fasting plasma glucose (FPG) was measured using a Synchron LX 20 analyzer 
(Beckman-Coulter) according to the manufacturer’s recommended protocol. Total cholesterol, triglycerides, and 
high-density lipoprotein (HDL) cholesterol levels were measured enzymatically using a Synchron LX20 analyzer 
(Beckman-Coulter, High Wycombe, UK). Plasma metanephrine and normetanephrine were measured by tandem 
mass spectrometry. The between-run coefficients of variation (CV) for the metanephrine and normetanephrine 
measurements were 6.5–12.2% and 4.7–11.5%, respectively. Urinary isoprostane, 8-iso PGF2α, was measured by 
enzyme-linked immunosorbent assay (ELISA) using urinary isoprostane EIA kit (Oxford Biomedical Research, 
Oxford, USA) as per the manufacturer’s protocol, and by an operator who was blinded to study group of the 
participants24.
Slow Off-rate Modified Aptamer (SOMA)-scan measurements. SOMAscan technology pro-
vides significant advantages in sample size, cost, time, multiplexing capability, dynamic range, and flexibility 
of readout over many alternate protein biomarker platforms. The protein quantification was performed using a 
Slow Off-rate Modified Aptamer (SOMAmer)–based protein array, as previously described25,26. Briefly, EDTA 
plasma samples were diluted and the following assay steps were performed: 1) binding – analytes and primer 
beads (PB)-SOMAmers (fully synthetic fluorophore-labeled SOMAmer coupled to a biotin moiety through a 
photocleavable linker) were equilibrated; 2) Catch 1 - all analyte/SOMAmers complexes were immobilized on a 
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streptavidin-substituted support. Washing steps removed proteins not stably bound to PB-SOMAmers and bound 
protein was biotinylated; 3) Cleave - long-wave ultraviolet light was applied to release analyte-SOMAmer com-
plexes into the solution; 4) Catch II – analyte-SOMAmer complexes were selectively immobilized on streptavidin 
support via the introduced analyte-borne biotinylation. Further washing was continued to select against unspe-
cific analyte/SOMAmer complexes; 5) Elution – Denaturation caused disruption of analyte-SOMAmer com-
plexes. Released SOMAmers serve as surrogates for quantification of analyte concentrations; 6) Quantification 
– hybridization to custom arrays of SOMAmer-complementary oligonucleotides.
Normalization of raw intensities, hybridization, median signal and calibration signal were performed based 
on the standard samples included on each plate, as previously described27.
We used version 3.1 of the SomaScan Assay, specifically targeting those proteins that have been linked with 
inflammation and oxidative stress in the SomaScan panel; at baseline, at the point of hypoglycemia and at 
24 hours.
Endo-Pat2000. Endo-PAT2000 was obtained from Itamar Medical Ltd, Israel. Endo-Pat was performed at 
baseline and at 24 hours following the clamp study. All tests were performed by the same operator, with the sub-
ject in the fasting state, and in a quiet and temperature-controlled room (23 °C) with the participant relaxed in a 
semi-recumbent position. Probes were placed on the index finger of each arm to measure peripheral arterial tone 
(PAT). PAT was recorded in both arms for the duration of the test. After 5 minutes of rest (baseline), the blood 
pressure cuff was inflated to 220–230 mmHg to stop the blood supply in the study arm for 5 minutes, and then 
deflated to release the blood supply for a further 5 minutes. A reactive hyperemic index (RHI) is a measure of 
the change in PAT in the study arm after occlusion compared to baseline, and adjusted for changes in the control 
arm. Bonetti et al.28 reported that a measurement of RHI lower than the cut-off value of 1.67 provides a sensitivity 
of 82% and a specificity of 77% in diagnosing coronary endothelial dysfunction. Endo-PAT reproducibility was 
within acceptable limits, ICC = 0.74, and coefficient of variation 12 ± 2.2%29.
Statistical analysis. This was a discovery study and no power analysis could be undertaken given that no 
similar studies have been undertaken. Data trends were visually evaluated for each parameter and non-parametric 
tests were applied on data that violated the assumptions of normality when tested using the Kolmogorov-Smirnov 
Test. Within group comparisons are as follows: changes from baseline at each stage (euglycemia, hypoglycemia 
and 24 hours) were compared using the paired t-test (or Wilcoxon signed-rank test for non-normally distributed 
data). Repeated measures were compared by analysis of variance (ANOVA); non-normally distributed data were 
log-transformed. The sample size was too small to adjust for baseline covariates. A two tailed p value of <0.05 was 
considered statistically significant. ANOVA post-hoc comparisons were adjusted using the Sidak test, to correct 
for multiple comparisons. Statistical analysis was performed using the Predictive Analytics Software (PASW) 
statistics 25 package (Statistical Package for the Social Sciences (SPSS) Inc., Chicago, USA)24.
For the proteomic analysis we fitted an intercept-free general linear model as a function of subgroup (i.e. 
condition:timepoint), while taking the patient identification (ID) as a random effect using the R package limma. 
Subsequently, we computed the p value for two contrasts: baseline to hypoglycemia for both T2DM and controls, 
and false discovery rate (FDR) corrected at a value of <0.05 as the cutoff for significance.
Ethics approval and consent to participate. The study was approved by the Yorkshire and the Humber 
Research Ethics Committee and all study participants signed an informed consent form prior to participation.
Consent for publication. All authors gave their consent for publication.
Results
18 participants were recruited (10 people with T2DM, 8 controls). In the T2DM group, the median duration of 
diabetes was 10 months (range 5–24 months); seven participants (70%) were on metformin therapy, while three 
were diet controlled. Participants’ demographics and baseline characteristics are summarized in Table 1.
Biochemical markers. For the inflammatory marker panel, comparison of baseline to hypoglycemia in 
T2DM subjects showed 15 proteins of 140 that were significantly different (Table 2) after multiple comparison 
testing: C-X-C motif chemokine 10 (CXCL10), Interleukin-5 (IL5), Azurocidin (AZU1), C-type lectin domain 
family 7 member A (CLEC7A), Serine/threonine-protein kinase (TBK1), Protein kinase C zeta type (PRKCZ), 
Ribosomal protein S6 kinase alpha-5 (RPS6KA5), CD40 ligand (CD40LG), Interleukin-34 (IL34), High mobility 
group protein B1 (HMGB1), Protein S100-A9 (S100A9), Interleukin-1 beta (IL1B), C-C motif chemokine 19 
(CCL19), Sialoadhesin (SIGLEC1) and Interleukin 10 receptor beta subunit (IL10RB). Comparison of T2DM 
and controls revealed that 4 proteins remained significantly different (Table 2) after multiple comparison testing: 
Prostaglandin G/H synthase 2 (PTGS2), HMGB1, IL5 and CXCL10. Ingenuity Pathway Analysis showing com-
munication between adaptive and innate immune cells via direct cell-to-cell contact, cytokines and chemokines 
is shown in Fig. 1.
Details of the panel of all of the inflammatory proteins measured are shown in Supplementary Tables 1 and 2 
for diabetes patients and controls, respectively; it can be seen therein that other proteins were showing a trend of 
deregulation, but were not significantly different, likely due to the small sample size. A comparison of baseline to 
24 hours showed no difference in any of the SomaScan proteins identified.
In both control and T2DM subjects, the inflammatory marker hsCRP increased maximally at 24 hours 
after induction of hypoglycemia, but the increase was significantly relevant only in the T2DM group (p < 0.01) 
(Table 3).
A subgroup analysis on males and females alone did not show significant differences between the genders and 
therefore the results were pooled.
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In the oxidative stress marker panel, only PTGS2 differed between T2DM and controls (p < 0.0001), and com-
parison of baseline to hypoglycemia in T2DM subjects showed fibroblast growth factor 8 (FGF8) (p < 0.0001) was 
significantly different, after multiple testing correction.
Whilst isoprostane (an oxidative stress marker) levels increased in both groups at 24 hours post clamp, only in 
T2DM were they significantly different from baseline (p < 0.05) (Table 3).
In both T2DM and control groups, plasma metanephrine significantly increased during the hypoglycaemic 
clamp and returned to baseline after 24 hours (Table 3), though between group changes did not differ. There was 
no significant change in plasma normetanephrine during the study in either group.
A subgroup analysis on males and females alone did not show significant differences between the genders and 
therefore the results were pooled.
Endothelial function. There was no significant change, in either group, in RHI at 24 hours compared to 
baseline (Table 3).
T2D (n = 10) Controls (n = 8)
Age (years) 47.0 (42.0–51.5) 47.5 (40.8–52.8)
Males (%) 8 (80%) 5 (62.5%)
Weight (kg) 103.1 (87.0–109.1) 85.5 (71.7–99.2)
BMI (kg/m2) 35.8 (27.3–40.9) 28.2 (24.2–32.8)*
Waist circumference (cm) 117.0 (99.5–124.7) 91.0 (82.9–111.3)*
Hip circumference (cm) 113.9 (105.8–128.2) 103.0 (99.5–113.7)
Waist/hip 0.99 (0.91–1.1) 0.90 (0.83–0.98)
Systolic BP (mmHg) 132 (111–142) 123 (116–132)
Diastolic BP (mmHg) 74 (68–85) 76 (69–82)
Cholesterol (mmol/L) 5.3 (4.4–5.7) 5.6 (4.2–5.7)
Triglycerides (mmol/L) 1.3 (0.98–2.2) 1.3 (0.78–1.5)
HDL (mmol/L) 1.2 (0.98–1.4) 1.3 (1.2–1.3)
LDL (mmol/L) 3.2 (2.8–3.7) 3.5 (2.7–3.7)
Chol/HDL 3.9 (3.6–5.8) 4.0 (3.4–4.3)
HbA1C (mmol/mol) 45.5 (39–56.3) 34 (31–36)*
HbA1C (%) 6.3 (5.7–7.3) 5.3 (5.0–5.4)*
Table 1. Demographic and baseline characteristics of study participants. Data presented as median (25th/75th 
centiles). Waist/hip, waist to hip ratio; BP, blood pressure; HDL, high density lipoprotein; LDL, low density 
lipoprotein; Chol/HDL, cholesterol to HDL ratio; HbA1C, hemoglobin A1C. *P < 0.05.
Protein UniProt
T2D Control
beta p-value beta p-value
Interleukin-5 P05113 0.39 2.78*10−04 0.20 1.30*10−01
Azurocidin P20160 0.47 5.75*10−04 −0.25 1.32*10−01
Ribosomal protein S6 kinase alpha-5 O75582 0.44 1.75*10−03 −0.24 1.62*10−01
CD40 ligand P29965 0.49 1.75*10−03 −0.36 5.64*10−02
High mobility group protein B1 P09429 0.39 2.20*10−03 0.39 1.25*10−02
Interleukin-34 Q6ZMJ4 −0.19 1.99*10−03 0.12 1.00*10−01
C-X-C motif chemokine 10 P02778 −0.54 2.61*10−04 −0.22 2.19*10−01
Protein S100-A9 P06702 0.52 2.82*10−03 0.23 2.81*10−01
C-C motif chemokine 19 Q99731 −0.33 4.16*10−03 −0.16 2.51*10−01
Sialoadhesin Q9BZZ2 −0.18 4.26*10−03 −0.07 3.80*10−01
Serine/threonine-protein kinase TBK1 Q9UHD2 0.25 1.20*10−03 −0.07 4.42*10−01
C-type lectin domain family 7 member A Q9BXN2 0.55 7.59*10−04 0.13 5.11*10−01
Protein kinase C zeta type Q05513 0.29 1.71*10−03 0.06 5.76*10−01
Interleukin-1 beta P01584 0.70 4.13*10−03 −0.17 5.77*10−01
Interleukin-10 receptor subunit beta Q08334 −0.16 4.67*10−03 0.03 6.24*10−01
Prostaglandin G/H synthase 2 P35354 0.15 6.73*10−02 0.44 5.33*10−05
Fibroblast growth factor 8 isoform A P55075 0.56 1.34*10−03 −0.25 2.10*10−01
Table 2. Inflammatory stress protein panel in patients with type 2 diabetes from baseline following 
hypoglycemia showing the 15 of 140 proteins that were significantly altered with a false discovery rate (fdr) of 
<0.05; the “beta” indicates the beta coefficient and reflects the direction of change.
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Discussion
Inflammatory regulators were increased at the time of hypoglycemia and, despite returning to normal at 24 hours, 
there was a residual effect on inflammation as seen by the increase in the inflammatory marker CRP. In line with 
the study objective, we found that these inflammatory changes were exaggerated in T2DM in comparison with 
the controls that showed a significant increase in only one inflammatory protein in contrast to T2DM where 15 
significantly altered proteins were identified. Additionally, CRP was elevated at 24 hours in T2DM but not in 
controls. Others have reported an increase in inflammation at the time of hypoglycemia7,8,30 and with an increase 
in both prothrombotic and proinflammatory parameters in type 1 diabetes23, but not in such a comprehensive 
manner looking at a broad proteomic approach of inflammatory proteins. Residual inflammation with an ele-
vated CRP at 24 hours has not previously been reported in people with T2DM. This suggests that the enhanced 
basal inflammation recognized in T2DM has an exaggerated effect in response to hypoglycemia that is persistent 
because, although the proteomic markers had returned to baseline at 24 hours, no time course was done after the 
hypoglycemic event to determine precisely when inflammation returned to baseline.
The majority of the inflammatory proteins that were found to be significantly elevated have been associ-
ated with increased cardiovascular disease such as, interleukin-5, cluster of differentiation 40 (CD40) and 
interleukin-1beta31, whilst FGF8 has been more associated with vascular remodeling.
Amongst the oxidative stress markers, only FGF8 was elevated and differentiated T2DM from controls. The 
elevation in FGF8 may suggest activation of protective mechanisms as FGF8 has been shown to inhibit oxidative 
stress32 and to protect neurons from oxidative stress33 in an in vitro setting. A residual effect on oxidative stress, 
with an elevation in urinary isoprostanes after 24 hours, was evident in T2DM subjects but not in non-diabetic 
controls. The urine collection at 24 hours was a spot urine that would reflect overnight urine production and was 
not collected at the time of the hypoglycemic event, suggesting that the induced oxidative stress continued for a 
period after the event. It is unclear if an exaggerated inflammatory response with more inflammatory markers 
resulted in enhanced oxidative stress, or if, conversely, the oxidative stress led to inflammation, or if indeed the 
result was an additive effect of both; more time points over the 24 hours period would be needed to determine 
this.
Oxidative stress is directly linked to vascular inflammation, precipitating both endothelial cell dysfunction 
and vascular damage14. There were no changes in endothelial function seen in this study at 24 hours; however, it 
was not possible technically to undertake the Endo-Pat at the time of hypoglycemia concomitantly with the insu-
lin clamp, and changes at this time point may have been missed. This result differs from a report using flow medi-
ated vasodilation7 wherein endothelial function was reduced following hypoglycemia but was, in fact, blunted by 
Figure 1. Ingenuity Pathway Analysis showing communication between adaptive and innate immune cells via 
direct cell-to-cell contact, cytokines and chemokines.
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repeated hypoglycemia, raising the question of whether clamping the hypoglycemia for one hour was responsible 
for this difference.
The Ingenuity Pathway Analysis (IPA) of the inflammatory proteins showed enrichment in the canonical 
pathways associated with communication between innate and adaptive immune cells (Supplementary Table 2). 
The innate immune response resulting in inflammation depends upon recognition of pattern-recognition recep-
tors (PRRs). PRRs are expressed mainly in immune and inflammatory cells such as monocytes, neutrophils 
and antigen-presenting cells (APCs) including macrophages and dendritic cells34,35. The association shown in 
the ingenuity pathway suggests that activation of PRRs resulted, leading to the induction of the inflammatory 
response with proinflammatory cytokines and type I interferons (interferon-α and interferon-β)36. These data 
are in accord with the proinflammatory effects reported following induced hypoglycemia with mobilization of 
the leukocyte response and induction of proinflammatory changes in immune cells that may promote a sustained 
inflammatory state37.
It is well recognized that inflammation is associated with adverse cardiac events and elevated levels of CRP, 
and other inflammatory biomarkers have been associated with multiple cardiovascular endpoints38 as well as 
sudden cardiac death39. An increase in oxidative stress leading to the overproduction of reactive oxygen species, 
which is often toxic to cells, causing damage to all components of the cells, such as proteins, DNA, and lipids20. 
Oxidative stress is known to be a major injury mechanism implicated in the pathogenesis of disease progression 
including ischemic myocardial injury, and may be caused by, or result in, inflammation14. In a population study, 
an increase in proinflammatory markers was related to hypoglycemia but not to macrovascular complications40. 
Our data suggest that the adverse effects of hypoglycemia on both inflammation and oxidative stress may persist 
well beyond the normalization of blood glucose levels.
In a recent large observational study in T2DM subjects41, strict glycemic control, with a median HbA1C 
of 6.4%, was associated with increased all-cause as well as cardiovascular mortality. In addition, in the three 
large trials: Action to Control Cardiovascular Risk in Diabetes (ACCORD)3, Action in Diabetes and Vascular 
Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE)2 and Veterans Affairs Diabetes Trial 
(VADT)4, which failed to show cardiovascular benefit with strict glycemic control in T2DM subjects, participants 
in the intensive treatment arm had significantly more episodes of severe hypoglycemia. Hypoglycemia was not 
thought to explain the increased mortality rate in the intensive treatment arm of the ACCORD study42 though no 
accountable cause was identified42–45. However, a link between hypoglycemia and increased mortality may exist, 
especially as episodes of hypoglycemia might pass unrecognized and self-reporting of hypoglycemia is known to 
be inaccurate. Furthermore, a cardiac event may not be linked to an episode of hypoglycemia occurring 24 hours 
previously. Enhanced inflammation and increased oxidative stress may contribute to the underlying mechanism 
of the association of hypoglycemia with subsequent cardiac death.
An increase in metanephrine levels was expected with hypoglycaemia in both groups as we have shown 
before46 indicative of the physiological response; however, there was the suggestion that the response was blunted 
in T2DM, though there was no statistical difference between groups.
The strengths of this study include the inclusion of a group of T2DM subjects who were relatively treatment 
naïve and not on poly-pharmacy, and an age-matched healthy control group. The main study limitation is the 
small study numbers and, with a larger population, the robust response to the number of inflammatory proteins 
increased by hypoglycemia may have been greater. Those with T2DM were more obese than the controls and 
it cannot be excluded that obesity may have contributed to the enhanced inflammatory response. The treat-
ment of those with T2DM may have altered the inflammatory responses. The changes that were looked for were 
at 24 hours and whilst the changes in oxidative stress and inflammation in T2DM were clearly significant at 
Group Sample Baseline Euglycaemia Hypoglycaemia 24 hours Comments
T2D
Metanephrine (80–510) pmol/L 86 (42–122) 121 (71–147) 284 (199–308)^ 101 (58–128) ANOVA (P = 0.001)
Normetanephrine (120–1180) pmol/L 153 (127–223) 143.5 (81–262) 157 (128–282) 202 (133–232) ANOVA (P = 0.9)
hsCRP(0–8) mg/L 2.4 (1.2–5.4) 2.2 (1.6–6)* 2.1 (1.1–5.1) 3.9 (1.8–6.1)^ ANOVA (P = 0.01)
RHI 2.0 (1.7–2.7) 2.7 (2.0–3.2) P = 0.13
Urinary isoprostanes (ng/ml) 73.4 (58.1–96.5) 91.7 (76.1–97.0) P = 0.016
Controls
Metanephrine (80–510) pmol/L 153 (88–225) 150 (68–222) 415 (250–607)^^ 107 (66–183) ANOVA (P = 0.048)
Normetanephrine (120–1180) pmol/L 234 (157–324) 225 (183–241) 225 (154–358) 231 (177–301) ANOVA (P = 0.17)
hsCRP(0–8) mg/L 1.2 (0.9–2.3) 0.9 (0.4–2.4) 1.0 (0.7–2.4) 1.6 (1.0–2.7)^^^ ANOVA (P = 0.045)
RHI 2.0 (1.7–2.6) 2.1 (1.8–2.5) P = 0.80
Urinary isoprostanes (ng/ml) 53.7 (11.2–79.7) 85.0 (8.9–95.2) P = 0.28
Table 3. A comparison of biochemical, inflammatory and endothelial function markers during the insulin 
clamp. Data presented as median (25th/75th centiles). T2DM, type 2 diabetes mellitus; hsCRP, high sensitivity 
C-reactive protein; RHI, reactive hyperemic index. All significant P values are highlighted. *P < 0.05 compared 
to baseline and 24 hours. ^P < 0.05 compared to any other time point. ^P < 0.05 compared to euglycemia 
and 24 hours. ^^^P < 0.05 compared to baseline and hypoglycemia. All post-hoc comparisons are Sidak 
test adjusted. RHI = Reactive hyperemia index for endothelial function. CRP = C reactive protein. *P < 0.05 
compared to baseline and 24 hours. ^P < 0.05 compared to any other time point. ^^P < 0.05 compared to 
euglycaemia and 24 hours. ^^^P < 0.05 compared to baseline and hypoglycaemia. All post-hoc comparisons are 
Sidak test adjusted.
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24 hours, there were no changes in endothelial function that may have arisen prior to this; however, this does still 
raise many questions about the impact of hypoglycemia on cardiovascular events that may occur 24 hours later in 
this group of people with high cardiovascular risk. The choice of the patients with T2DM were those on diet alone 
and on a stable dose of metformin and it is unknown if a different oxidative or inflammatory response would be 
found in those patients on a sulphonylurea or on insulin therapy.
Conclusion
In conclusion, induced hypoglycemia significantly increased markers of inflammation and a marker of oxidative 
stress at the point of hypoglycemia, with increased integrative markers of both inflammation and oxidative stress 
at 24 hours following the hypoglycemic episode in T2DM subjects but not controls. This showed an increased 
inflammatory and oxidative stress response to hypoglycemia in T2DM that may be additive and generalizable 
to non-iatrogenically induced hypoglycemic episodes in subjects with T2DM, though endothelial function was 
unaffected.
Data availability
All the data for this study will be made available upon reasonable request to the corresponding author.
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